Mechanism of controlled release kinetics from medical devices

Brazilian Journal of Chemical Engineering

Volumn 27, Issue 2, 2010, Pages 211-225

  Raval, A ^a   Parikh, J ^a   Engineer, C ^b  

^a SARDAR VALLABHBHAI NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b Sahajanand Medical Technologies Pvt Ltd   (India)

Author keywords

Drug release kinetics; Polymers; Stent

Indexed keywords

ARTIFICIAL ORGANS; BIODEGRADABLE POLYMERS; BIOMEDICAL EQUIPMENT; DRUG PRODUCTS; FUNCTIONAL POLYMERS; KINETICS; POLYMERS; STENTS;

CARDIOVASCULAR STENTS; CHARACTERIZATION TECHNIQUES; CORONARY ARTERY BYPASS GRAFTING; DRUG RELEASE KINETICS; DRUG RELEASE MECHANISM; ENGINEERING PRINCIPLES; MEDICAL DEVICE INDUSTRY; STENT;

CONTROLLED DRUG DELIVERY;

EID: 77956220813     PISSN: 01046632     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-66322010000200001     Document Type: Article

References (76)

1. Acharya G., K. Park, Mechanisms of controlled drug release from drug-eluting stents. Advanced Drug Delivery Reviews, 58, 387-401 (2006).
2. Alexis, F., Venkatraman, S., Rath, S. K., Boey, F., In vitro study of release mechanisms of Paclitaxel and Rapamycin from drug-incorporated stent. Journal of Controlled Release, 98, 67-74 (2004).
3. Amidon, G., Lennernas, H., Shah, V., Crison, J., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12, 413-420 (1995).
4. Baim, D. S., Modalities to Minimise Polymer Toxicity: Abluminal Coatings, Bioabsorbable Polymers and More. Boston Scientific Corp. Lecture, Transcatheter Cardiovascular Therapeutics Conference, Washington, DC, USA (2007).
5. Balakrishnan, B., Dooley, J., Kopia, G., Edelman, E., Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. Journal of Controlled Release, 123, 100-108 (2007).
6. Balakrishnan, B., Tzafriri, A. R., Seifert, P., Groothuis, A., Rogers, C., Edelman, E. R., Strut Position, Blood Flow, and Drug Deposition Implications for Single and Overlapping Drug-Eluting Stents. Circulation, 111, 2958-2965 (2005).
7. Balss, K. M., Llanos, G., Papandreou, G., Maryanoff, C. A., Quantitative spatial distribution of Sirolimus and polymers in drug-eluting stents using confocal Raman microscopy. Journal of Biomedical Materials Research Part A, 85A, No.1, 258-270 (2007).
8. Center for Devices and Radiological Health Guidance, Guidance for Industry: Coronary Drug-Eluting Stents -Non-clinical and Clinical Studies (http://www.fda.gov/cdrh/ode/guidance/6255.html), (2008).
9. Chen, M. C., Liang, H. F., Chiu, Y. L., Chang, Y., Wei, H. J., Sung, H. W., A novel drug-eluting stent spray coated with multilayers of collagen and Sirolimus. Journal of Controlled Release, 108, 178-189 (2005).
10. Colombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., F. Schiele, K. Zmudka, G. Guagliumi, M.E. Russell, Randomized study to assess the effectiveness of slow-and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation, 108, 788-794 (2003).
11. Creel, C., Lovich, M., Edelman, E., Arterial Paclitaxel distribution and deposition. Circulation Research, 86, 879-884 (2000).
12. Deconinck, E., Sohier, J., De Scheerder, I., Van Den Mooter, G. Pharmaceutical Aspects of Drug Eluting Stents. Journal of Pharmaceutical Sciences, 97, No.12, 5047-5060 (2008).
13. Diener, T., Hensel, B., Heublein, B., Barlach, S., Rohde, R., Sternberg, K., Schmitz, K. P., Harder, C., Hartwig, S., Tittelbach, M., Biodegradable Drug Depots on Coronary Stents -Local Drug Delivery in Interventional Cardiology. Progress in Biomedical Research, 8, No.2, 82-91 (2003).
14. Domb, A., Amselem, S., Shah, J., Maniar M., Degradable polymers for site-specific drug delivery. Polymers for Advanced Technologies, 3, No.6, 279-292 (2003).
15. Dubin C. H., A one-two punch: drug/medical device combination products are taking healthcare in a new direction. Is the pharmaceutical industry prepared? Drug Delivery Technology, 4 (2004).
16. Finkelstein, A., McClean, D., Kar, S., Takizawa, K., Varghese, K., Baek, N., Park, K., Fishbein, M. C., Makkar, R., Litvack, F., Eigler, N. L., Local Drug Delivery via a Coronary Stent with Programmable Release Pharmacokinetics. Circulation, 107, 777-784 (2003).
17. Finn, A. V., Nakazawa, G., Joner, M., Kolodgie, F. D., Mont, E. K., Gold, H. K., Virmani, R., Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1500-1510 (2007).
18. Frank, A., Rath, S. K., Boey, F., Venkatraman, S., Study of the initial stages of drug release from a degradable matrix of poly(d,l-lactide-coglycolide) . Biomaterials, 25, 813-821 (2004).
19. Frohoff-Hülsmann, M. A., Lippold, B. C., McGinity, J. W., Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and hydroxypropyl methyl cellulose as coating material for diffusion pellets I: Drug release rates from coated pellets. International Journal of Pharmaceutics, 177, 69-82. (1999).
20. Grassi, M., Grassi, G., Mathematical Modelling and Controlled Drug Delivery: Matrix Systems. Current Drug Delivery, 2, No.1, 97-116 (2005).
21. Grube, E., Buellesfeld, L., BioMatrix Biolimus A9-eluting coronary stent: a next-generation drugeluting stent for coronary artery disease. Expert Review of Medical Devices, 3, No. 6, 731-741 (2006).
22. Hara, H., Nakamura, M., Palmaz, J., Schwartz, R., Role of stent design and coatings on restenosis and thrombosis. Advanced Drug Delivery Reviews, 58, 377-386 (2006).
23. Hausleiter, J., Kastrati, A., Wessely, R., Dibra, A., Mehilli, J., Schratzenstaller, T., Graf, I., Renke-Gluszko, M., Behnisch, B., Dirschinger, J., Wintermantel, E, Schomig, A., Prevention of restenosis by a novel drug eluting stent system with a dose-adjustable polymer free on-site stent coating. European Heart Journal, 26, 1475-1481 (2005).
24. Heldman, A., Cheng, L., Jenkins, G., Heller, P., Kim, D., Ware, M., Nater, C., Hruban, R., Rezai, B., Abella, B., Bunge, K., Kinsella, J., Sollott, S., Lakatta, E., Brinker, J., Hunter, W., Froehlich, J., Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis. Circulation, 103, 2289-2295 (2001).
25. Heller, J., Baker, R. W., Theory and practice of controlled drug delivery from bioerodible polymers. In, Controlled Release of Bioactive Materials (R.W. Baker Ed.), New York: Academic Press, p. 1-18 (1980).
26. Higuchi, T., Rate of release of medicaments from ointment bases containing drugs in suspensions. Journal of Pharmaceutical Sciences. 50, 874-875 (1961).
27. Higuchi, T., Mechanism of sustained medication. Theoretical analysis of rate of solid drugs dispersed in solid matrices. Pharmaceutical Sciences, 52, No.12, 1145-1149, (1963).
28. Hose, D. R., Narracott, A. J., Griffiths, B., Mahmood, S., Gunn, J., Sweeney, D., Lawford, P.V., A Thermal Analogy for Modeling Drug Elution from Cardiovascular Stents. Computer Methods in Biomechanics and Biomedical Engineering, 7, No.5, 257-264 (2004).
29. Hurrell, S., Cameron R., The effect of initial polymer morphology on the degradation and drug release from poly glycolide. Biomaterials, 23, 2401-2409 (2002).
30. Hwang, C. W., Wu, D., Edelman, E. R., Physiological transport forces govern drug distribution for stent-based delivery. Circulation, 104, 600-605 (2001).
31. Hwang, C. W., Wu, D., Edelman, E. R., Impact of Transport and Drug Properties on the Local Pharmacology of Drug-Eluting Stents. International Journal of Cardiovascular Interventions, 5, 7-12 (2003).
32. Jonnalagadda, S., Robinson, D., A Bioresorbable, Poly lactide Reservoir for Diffusional and Osmotically Controlled Drug Delivery. AAPS Pharmaceutical Science and Technology, 1, No.4, 26-34, (2000).
33. Kamath, K. R., Barry, J. J., Miller, K. M., The Taxus™ drug-eluting stent: A new paradigm in controlled drug delivery. Advanced Drug Delivery Reviews, 58, 412-436 (2006).
34. Kothwala. D., Raval. A., Choubey, A., Engineer, C., Kotadia H., Paclitaxel Drug Delivery from Cardiovascular Stent. Trends in Biomaterials & Artificial Organs, 19, No.2, 88-92 (2006).
35. Langer R. S., Wise (eds) D. L., Medical Applications of Controlled Release, Applications and Evaluation. Vol.I and II, CRC Press, Boca Raton, Florida (1984).
36. Langer, R., New methods of drug delivery. Science 249, 1527-1533 (1990).
37. Lee, P. I., Diffusional release of a solute from a polymeric matrix -approximate and analytical solutions. Journal of Membrane Sciences, 7, 255-275 (1980).
38. Leon, M. B., Endeavor IV: A Randomized Comparison of a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. Transcatheter Cardiovascular Therapeutics, Washington D.C. (2007).
39. Leon, M. B., Abizaid, A., Moses, J. W., The CYPHER™ Stent: A New Gold Standard in the Treatment of Coronary Artery Disease, The Cardiovascular Research Foundation, New York, NY (2003).
40. Lovich, M. A., Creel, C. J., Hong, K., Hwang, C. W., Edelman, E. R., Carrier proteins determine local pharmacokinetics and arterial distribution of Paclitaxel. Journal of Pharmaceutical Sciences, 90, No.9, 1324-1335 (2001).
41. Lovich, M. A., Philbrook, M., Sawyer, S., Weselcouch, E., Edelman, E. R. Arterial heparin deposition: role of diffusion, convection, and extravascular space. American Journal of Physiology, Heart and Circulatory Physiology, 275, 2236-2242 (1998).
42. Migliavacca, F., Petrini, L., Colombo, M., Auricchio, F., Pietrabissa, R., Mechanical behavior of coronary stents investigated through the finite element method. Journal of Biomechanics, 35, 803-811 (2002).
43. Miyajima, M., Koshika, A., Okada, J., Ikeda, M., Mechanism of drug release from poly(l-lactic acid) matrix containing acidic or neutral drugs. Journal of Controlled Release, 60, No.2-3, 5, 199-209 (1999).
44. Moussa, I., Leon, M. B., Baim, D. S., O'Neill, W. W., Popma, J. J., Buchbinder, M., Midwall, J., Simonton, C. A., Keim, E., Wang, P., Kuntz, R. E., Moses, J. W., Impact of Sirolimus-Eluting Stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions) sub study. Circulation. 109, 2273-2278 (2004).
45. Okarter, T. U., Singla, K., The effects of plasticizers on the release of metoprolol tartrate from granules coated with a polymethacrylate film. Drug Development and Industrial Pharmacy, 26, 323-329 (2000).
46. Otsuka, Y., Chronos, N., Apkarian, R., Robinson, K., Scanning Electron Microscopic Analysis of Defects in Polymer Coatings of Three Commercially Available Stents: Comparison of BiodivYsio, Taxus and Cypher Stents. Journal of Invasive Cardiology, 19, No.2, 71-76 (2007).
47. Pan, C., Tang, J., Weng, Y., Wang, J., Huang, N., Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. Journal of Controlled Release, 116, No.1, 42-49 (2006).
48. Pillai, O., Dhanikula, A. B., Panchagnula R., Drug delivery: An odyssey of 100 years. Current Opinion in Chemical Biology, 5, No.4, 439-446 (2001).
49. Prabhu, S., Computational Modelling in Stent-based Drug Delivery. Business Briefing: Medical Device Manufacturing & Technology, 41-42 (2004).
50. Prabhu, S., Hossainy, S., Modeling of degradation and drug release using biodegradable stent coating. Journal of Biomedical Materials Research Part A, 80A, No.3, 732-741 (2006).
51. Ranade, S. V., Miller K. M., Richard, R. E., Chan, A. K., Allen, M. J., Helmus, M. N., Physical characterization of controlled release of Paclitaxel from the TAXUSTM Express2TM drug-eluting stent. Journal of Biomedical Materials Research Part A, 71A, No.4, 625-634 (2004).
52. Ranade, S., Richard, R., Helmus, M., Styrenic block copolymers for biomaterial and drug delivery applications. Acta Biomaterialia, 1, 137-144 (2005).
53. Ratner, B. D., Hoffman, A. S., Schoen, F. J., Lemons, J. E., Biomaterials Science: An Introduction to Materials in Medicine. Academic Press, New York, p. 346-356 (1996).
54. Raval, A., Choubey, A., Engineer, C., Kotadia, H., Kothwala, D., Novel Biodegradable Polymeric Matrix Coated Cardiovascular Stent for Controlled Drug Delivery. Trends in Biomaterials & Artificial Organs, 20, No.2, 101-110 (2007).
55. Reis, A., Guilherme, M., Rubira, A., Muniz, E., Mathematical model for the prediction of the overall profile of in vitro solute release from polymer networks. Journal of Colloid and Interface Science, 310, 128-135 (2007).
56. Rosenthal, A., Abluminal Ultrathin Microstructure Coating, Lab Coat Limited (http://media. crtonline.org/slides/evan-Labcoat,Ltd.Ablumina l-03272007/a1020-ArthurRosenthal-LABCOA T-Fri.ppt), (2007).
57. Royce A., Li S., Weaver M., Shah, U., In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine. Journal of Controlled Release, 97, 79-90 (2004).
58. Saylor, D. M., Structure and Release Behavior in Controlled Drug Delivery Devices. Computational Homology Workshop, Georgia Tech, Atlanta GA (2006).
59. Schliecker, G., Schmidt, C., Fuchs, S., Kissel, T., Characterization of a homologous series of D,Llactic acid oligomers: a mechanistic study on the degradation kinetics in vitro. Biomaterials, 24, 3835-3844 (2003).
60. Sharkawi, T., Cornhill, F., Lafont, A., Sabaria, P. Vert, M., Intravascular bioresorbable polymeric stents: A potential alternative to current drug eluting metal stents, Journal of Pharmaceutical Sciences. 96, No.11, 2829-2837 (2007).
61. Shameem, M., Lee, H., DeLuca, P., A Short-term (Accelerated Release) Approach to Evaluate Peptide Release from PLGA Depot Formulations. The AAPS Journal, 1, No.3, 1-6 (1999).
62. Shao, Z. J., Moralesi, L., Diaz, S., Muhammadi, N.A., Drug release from Kollicoat SR 30D-coated nonpareil beads: evaluation of coating level, plasticizer type, and curing condition. AAPS Pharmaceutical Science and Technology, 3, No.2, 87-96 (2002).
63. Sternberg, K., Kramer, S., Nischan, C., Grabow, N., Langer, T., Hennighausen, G., Schmitz, K., In vitro study of drug-eluting stent coatings based on poly (L-lactide) incorporating cyclosporine A -drug release, polymer degradation and mechanical integrity. Journal of Materials Science: Materials in Medicine, 18, 1423-1432 (2007).
64. Streit, F., Christians, U., Schiebel, H. M., Napoli, K.L., Ernst, L., Linck, A., Kahan, B. D., Sewing, K. F., Sensitive and specific quantification of Sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray mass spectrometry. Clinical Chemistry, 42, No.9, 1417-1425 (1996).
65. Sun, H., Mei, L., Song, C., Cui, X., Wang, P., The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials, 27, No.9, 1735-1740 (2006).
66. Tesfamariam B., Drug Release Kinetics From Stent Device-Based Delivery Systems. Journal of Cardiovascular Pharmacology, 51, 118-125 (2008).
67. Vergara, C., Zunino, P., Multiscale modeling and simulation of drug release from cardiovascular stents. Report, MOX, Dipartimento di Matematica "F. Brioschi" Politecnico di Milano, Via Bonardi 29-20133 Milano (Italy), Report No. 15, (2007).
68. Venkatraman, S., Boey, F., Release profiles in drugeluting stents: Issues and uncertainties. Journal of Controlled Release, 120, 149-160 (2007).
69. Vetrovec, G., Rizik, D., Williard, C., Snead, D., Piotrovski, V., Kopia, G., Sirolimus PK trial: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. Catheterization and Cardiovascular Interventions, 67, 32-37 (2006).
70. Vranckx, P., Serruys, P. W., Ghambhir, D. S., Sousa, E., Abizaid, A., Lemos, P., Ribeiro, E., Dani, S., Dalal, J., Mehan, V., Dhar, A., Dutta, L., Reddy, K., Chand, R., Ray, A., Symons, J., Biodegradable polymer base Paclitaxel eluting Infinnium stent: 9 month clinical and angiographic follow up results from the SIMPLE II prospective multi centre registry study. Euro Intervention, 2, 310-317 (2006).
71. Waksman, R., Next Generations Drug Eluting Stents will safety be addressed? ACC 2007, 56th Annual Scientific Session, New Orleans (2007).
72. Wang, X., Venkatraman, S., Boey, F., Loo, J., Tan, L P., Controlled release of Sirolimus from a multilayered PLGA stent matrix. Biomaterials, 27, 5588-5595 (2006).
73. Wise, L. D., Handbook of pharmaceutical controlled release technology. Marcel Dekker, Inc. New York, Basel (2000).
74. Wolf, K. V., Zong, Z., Meng, J., Orana, A., Rahbar, N., Balss, K.M., Papandreou, G., Maryanoff, C. A., Soboyejo, W., An investigation of adhesion forces in drug eluting stent layers. Journal of Biomedical Materials Research Part A, 87A, No.1, 272-281 (2008).
75. XIENCE™V Everolimus Eluting Coronary Stent System (EECSS) PMA # P070015 (http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4333s1-03% 20-%20XIENCE%20V%20Panel-Abbott%20 Vascular %20 Presentation.pdf) (2007).
76. Yang, C., Burt, H., Drug-eluting stents: Factors governing local pharmacokinetics. Advanced Drug Delivery Reviews, 58, 402-411 (2006).